IFM Investors Pty Ltd Raises Stake in UiPath Inc. (NYSE:PATH)

IFM Investors Pty Ltd grew its stake in shares of UiPath Inc. (NYSE:PATH) by 7.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,458 shares of the healthcare company’s stock after purchasing an additional 6,357 shares during the quarter. IFM Investors Pty Ltd’s holdings in UiPath were worth $1,983,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Intech Investment Management LLC boosted its stake in shares of UiPath by 3.1% during the fourth quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after purchasing an additional 426 shares during the period. 180 Wealth Advisors LLC raised its holdings in shares of UiPath by 0.3% in the fourth quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock valued at $4,497,000 after acquiring an additional 492 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in shares of UiPath by 4.9% in the fourth quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after acquiring an additional 598 shares in the last quarter. Simplicity Solutions LLC raised its holdings in shares of UiPath by 4.9% in the fourth quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after acquiring an additional 598 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of UiPath by 40.2% in the first quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock valued at $50,000 after acquiring an additional 632 shares in the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Stock Performance

NYSE PATH traded up $0.05 during trading hours on Friday, reaching $19.46. The stock had a trading volume of 4,692,993 shares, compared to its average volume of 5,833,793. The stock has a fifty day moving average of $22.19 and a 200 day moving average of $21.61. The stock has a market cap of $11.07 billion, a P/E ratio of -114.47 and a beta of 0.96. UiPath Inc. has a 52-week low of $12.38 and a 52-week high of $27.87.

UiPath (NYSE:PATH) last issued its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. The firm had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. On average, equities research analysts forecast that UiPath Inc. will post -0.04 EPS for the current year.

Insider Activity at UiPath

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the sale, the chief financial officer now owns 103,505 shares in the company, valued at approximately $2,325,757.35. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold a total of 72,000 shares of company stock worth $1,591,360 over the last quarter. Insiders own 31.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on PATH shares. KeyCorp started coverage on UiPath in a report on Monday, April 8th. They issued an “overweight” rating and a $27.00 price objective for the company. Morgan Stanley lifted their price objective on UiPath from $17.00 to $25.00 and gave the company an “equal weight” rating in a report on Thursday, March 14th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price on shares of UiPath in a report on Wednesday, March 20th. Evercore ISI boosted their target price on shares of UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a report on Thursday, March 14th. Finally, Canaccord Genuity Group boosted their target price on shares of UiPath from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Nine analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, UiPath currently has an average rating of “Moderate Buy” and a consensus target price of $27.41.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.